Hologic (NASDAQ:HOLX) Updates Q4 2025 Earnings Guidance

Key Points

• Hologic has revised its Q4 2025 earnings guidance, forecasting an EPS of 1.090-1.120, which exceeds the consensus estimate of 1.073.
• The company's overall revenue guidance for the period remains steady at $1.0 billion, consistent with analysts' estimates.
• Recent analyst ratings show a mixed outlook, with Hologic earning a "Hold" rating from the majority, while target prices range from $62.00 to $77.33.

Hologic (NASDAQ:HOLX - Get Free Report) issued an update on its fourth quarter 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 1.090-1.120 for the period, compared to the consensus earnings per share estimate of 1.073. The company issued revenue guidance of $1.0 billion-$1.0 billion, compared to the consensus revenue estimate of $1.0 billion. Hologic also updated its FY 2025 guidance to 4.230-4.260 EPS.

Hologic Stock Up 0.5%

Shares of HOLX stock traded up $0.34 on Friday, hitting $67.16. 1,863,529 shares of the stock were exchanged, compared to its average volume of 1,799,668. The company has a current ratio of 3.55, a quick ratio of 2.52 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $14.97 billion, a P/E ratio of 27.87, a price-to-earnings-growth ratio of 2.42 and a beta of 0.49. The business has a 50-day moving average of $64.42 and a 200 day moving average of $62.81. Hologic has a fifty-two week low of $51.90 and a fifty-two week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, beating the consensus estimate of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%. The firm had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.01 billion. During the same period in the prior year, the firm posted $1.06 earnings per share. The business's quarterly revenue was up 1.2% compared to the same quarter last year. Equities analysts anticipate that Hologic will post 4.28 EPS for the current year.

Analyst Ratings Changes

Several analysts have issued reports on HOLX shares. Morgan Stanley upped their price objective on Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a research note on Thursday. Citigroup upgraded Hologic from a "neutral" rating to a "buy" rating and upped their price objective for the company from $60.00 to $80.00 in a research note on Wednesday, July 9th. Royal Bank Of Canada dropped their price objective on Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a research note on Friday, May 2nd. Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Finally, Mizuho set a $75.00 target price on Hologic in a research note on Thursday. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $76.42.

Insider Buying and Selling at Hologic

In other news, Director Martin D. Madaus acquired 5,445 shares of the business's stock in a transaction that occurred on Wednesday, May 7th. The shares were bought at an average price of $55.24 per share, with a total value of $300,781.80. Following the acquisition, the director directly owned 5,445 shares in the company, valued at $300,781.80. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 1.88% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Hologic stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 10.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 38,776 shares of the medical equipment provider's stock after purchasing an additional 3,520 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in Hologic were worth $2,395,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 94.73% of the company's stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.